Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756154 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL25982672 | 0.82 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL18856638 | 0.82 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL15965457 | 0.82 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL28995300 | 0.82 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL31584385 | 0.82 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL7077220 | 0.82 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL20046980 | 0.82 | MEN1 (0.46) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL720627 | 0.80 | TSHR (0.62) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL25031990 | 0.78 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | MEN1 940/4885KMT2A 1974/4885TSHR 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.